Order Article Reprints

Peters S, Wirkert E, Kuespert S, Heydn R, Johannesen S, Friedrich A, Mailänder S, Korte S, Mecklenburg L, Aigner L, et al. Safe and Effective Cynomolgus Monkey GLP—Tox Study with Repetitive Intrathecal Application of a TGFBR2 Targeting LNA-Gapmer Antisense Oligonucleotide as Treatment Candidate for Neurodegenerative Disorders. Pharmaceutics. 2022; 14(1):200. https://doi.org/10.3390/pharmaceutics14010200

Peters, Sebastian, Eva Wirkert, Sabrina Kuespert, Rosmarie Heydn, Siw Johannesen, Anita Friedrich, Susanne Mailänder, Sven Korte, Lars Mecklenburg, Ludwig Aigner, and et al. 2022. "Safe and Effective Cynomolgus Monkey GLP—Tox Study with Repetitive Intrathecal Application of a TGFBR2 Targeting LNA-Gapmer Antisense Oligonucleotide as Treatment Candidate for Neurodegenerative Disorders" Pharmaceutics 14, no. 1: 200. https://doi.org/10.3390/pharmaceutics14010200

Peters, S., Wirkert, E., Kuespert, S., Heydn, R., Johannesen, S., Friedrich, A., Mailänder, S., Korte, S., Mecklenburg, L., Aigner, L., Bruun, T.-H., & Bogdahn, U. (2022). Safe and Effective Cynomolgus Monkey GLP—Tox Study with Repetitive Intrathecal Application of a TGFBR2 Targeting LNA-Gapmer Antisense Oligonucleotide as Treatment Candidate for Neurodegenerative Disorders. Pharmaceutics, 14(1), 200. https://doi.org/10.3390/pharmaceutics14010200